The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.

Inclusion Criteria:

• Male or female subjects, age > 18 years
• Primary hypercholesterolaemia with CV risk > 20% (as defined in European Guidelines ) and/or type II diabetes and/or a history of CHD or other established atherosclerotic disease. Subjects may be lipid-lowering therapy naïve or have been treated for min. 4 weeks with a 'start' dose of any lipid-lowering therapy, which was ineffective.
• Naïve subjects must have completed 12-weeks dietary counselling before this visit.

Exclusion Criteria:

• Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
• Documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3.
• Serious or unstable medical condition
• Statin contraindication